a Platycodi radix (Jiegeng) is commonly used as a channel ushering drug for assistance in treating respiratory diseases, because of the activities of saponins that are called platycosides. In this study, using ultra high pressure liquid chromatography with quadrupole time of flight mass spectrometry (UPLC-Q/TOF-MS) and a strategy based on fragmentation behaviors, a total of thirteen platycosides were identified in the total saponins, and seven of these were found in rat plasma following a single oral dose of total saponins. The secondary platycosides were proved to be the main absorbed saponins in vivo. AE 0.82 at a dose of 350 mg kg À1 . The above pharmacokinetic parameters were higher than those of GP at the same dosage, which showed that GPA was likely to be the main absorbed saponin in vivo. These findings provide useful information that will support the studies on identification of bioactive platycosides in vivo, and will lay the foundation for the development of Jiegeng.
Introduction
Platycodi radix (Jiegeng), the dried root of Platycodon grandiorum A. DC. (Campanulaceae), has been widely used as an antitussive or anti-inammatory medicine in China and East Asia. [1] [2] [3] In addition, Jiegeng has been reported to have many other pharmacological activities, such as anti-oxidant, 4, 5 antitumor, [6] [7] [8] [9] anti-diabetic, 10 anti-obesity, 11, 12 hepato-protective 13, 14 and cardiovascular system activities. 15, 16 All the above activities are due to the chemical constituents in Jiegeng, including polysaccharides, saponins, avonoids, polyphenols, polyacetylenes and sterols. 1 The saponins in Jiegeng are also called platycosides, which have been proved to be the major bioactive compounds. 17 Currently, all known platycosides are oleananetype pentacyclic triterpenoid saponins, which are mostly primary saponins. 18 These platycosides primarily have two saccharide chains; one or two glucoses linked through linear glycosidic bonds at the C-3, and arabinose, rhamnose, xylose and apiose sequentially attached at C-28 by ester linkages.
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According to the different aglycones, they are classied into four types, including paltcodic acid, polygalic acid, platcogenic acid and its derivatives.
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Although there are a large number of studies about the activities of platycosides at present, there are only a few studies on the pharmacokinetics of platycosides. The pharmacokinetic studies of platycodin D, platycodin D3 and deapioplatycodin D have shown that these platycosides have low oral bioavailability, which due to the poor permeability and degradation in the gastrointestinal tract. [20] [21] [22] [23] [24] [25] In that case, we consider that activities of Jiegeng could be caused by the metabolites of platycosides or other absorbed platycosides.
In this study, the total saponins were isolated from the platycodi radix extract, and the main platycosides were identied by the ultra high pressure liquid chromatography along with quadrupole time of ight mass spectrometry (UPLC-Q/TOF-MS). According to the result of identication based on the fragmentation behaviors of platycosides, the absorbed saponins were qualitatively analyzed by principal components analysis (PCA). Then, the secondary platycosides, 3-O-b-D-glucopyranosylplatycodigenin (GP) and 3-O-b-D-glucopyranosylplatyconic acid (GPA), with higher relative contents were isolated and identied. And their pharmacokinetic parameters were evaluated using the liquid chromatography along with triple quadrupole mass spectrometry (LC-QQQ). By this way, we hoped to utilize the information about metabolites of platycosides to discover the bioactive constituents in vivo, and provide pharmacokinetic data support for subsequent pharmacological experiments.
Materials and methods

Chemicals, reagents and animals
Platycodi radix extract (bath number TR20160103) was purchased from Tianrui Bio-Tech Co., Ltd (Xi'an, China). Acetonitrile (HPLC grade) and methanol (HPLC grade) were purchased from Merck (Darmstadt, Germany). Ultrapure water was prepared with a Milli-Q system (Millipore, Bedford, MA, USA). All other reagents were analytical grade and purchased from Concord Technology (Tianjin, China). Ginsenoside Rh1 (98% purity) was purchased from the Shilan Technology (Tianjin, China).
Experimental animals were purchased from the Laboratory Animal Center of the Academy of Military Medical Sciences (SCXK 2012-0004, Beijing, China). The animals were housed under standard laboratory conditions (25 AE 1 C, 50 AE 10% humidity, and 12 h photoperiod) with free access to food and water. The animal experiments were approved by the Animal Experiments Ethical Committee of Nankai University and complied with the Guide for the Care and Use of Laboratory Animals. The animals were fasted 12 h and had free access to water throughout the experimental period.
Instrumentation and conditions
The UPLC-Q/TOF-MS system consisted of a Waters Acquity UPLC System (Waters Co., Milford, MA, USA) and a Waters Q/ TOF Premier instrument with an electrospray ionization system (Waters MS Technologies, Manchester, UK). An Acquity BEH C18 column (2.1 mm Â 100 mm, 1.7 mm; Waters Co.) was used with a mobile phase of 0.1% formic acid (A)-acetonitrile (B). The elution gradient was as follows: 0 min, 5% B; 2 min, 15% B; 18 min, 35% B. 23 min, 55% B; 27 min, 100% B; 29 min 100% B. The ow rate was 0.40 mL min À1 and the column temperature was maintained at 30 C. The injection volume of the test sample was 5 mL. Data were acquired using MassLynx V4.1 soware (Waters Co.). The capillary voltage was set to 2.0 kV for the negative mode and 3.0 kV for the positive mode, and the sample cone voltage was set to 40 V. The desolvation gas was set to 800 L h À1 at a temperature of 450 C, the cone gas was set to 50 L h À1 , and the source temperature was 120 C. The mass spectrometric data were collected in full scan mode, and the m/z ranged from 50 to 1900 Da in the positive and negative ion modes.
The LC-QQQ platform was comprised of an Agilent 1290 innity ultra-high performance liquid chromatography (UHPLC) system (Agilent Technologies, Santa Clara, USA) interfaced to an Agilent 6490 Triple Quadrupole LC/MS System (Agilent Technologies, Santa Clara, USA), using a standard-ow ESI (Jet Stream) source. The LC system specically consists of a binary pump, a thermostatted column compartment, and a thermostatted micro well-plate autosampler. The column was an Acquity BEH C18 column (2.1 mm Â 100 mm, 1.7 mm; Waters Co.), and the mobile phase consisted of 0.1% formic acid (A) and acetonitrile (B) using a gradient elution program as follows: 0 min, 30% B; 8 min, 35% B; 10 min, 85% B. 10.1 min, 100% B; 12 min, 100% B. The column temperature was set to 25 C, the ow rate was maintained at 0.35 mL min À1 , and the injection volume was set at 2 mL. All data are processed with the Agilent MassHunter Quantitative Analysis soware (version B.06.00, Agilent Technologies). The capillary voltage was set to 4.0 kV for the positive mode, and the fragmentor voltage was 250 V. The sheath gas was set to 16 L min À1 at a temperature of 250 C. The nebulizer gas pressure was 35 psi.
2.3. Metabolite identication of the total saponins 2.3.1. Preparation of the total saponins. The powder of platycodi radix extract (600 g) was precipitated with 70% ethanol (2 L). Aer ltration, the supernatants were evaporated under reduced pressure. The extract was chromatographed over a macroporous resin AB-8 column and eluted in accordance with the order of water, 30% ethanol, and 70% ethanol. The 70% ethanol fraction was collected, evaporated and lyophilised to obtain total saponins (5.14 g). The powder of total saponins was prepared into 50% methanol solution with a concentration of 3 mg mL À1 and ltered through a 0.22 mm lter before the UPLC-Q/TOF-MS analysis.
Metabolite identication of the total saponins in vivo.
Ten male SD rats were divided into experimental and control group randomly. In the experimental group, total saponins were administered orally at a dose of 600 mg kg À1 body weight, and the control group was given physiological saline in the same manner. Aer 30 min of administration, the rats were anesthetized by 10% chloral hydrate (0.3 mL/100 g), and the blood samples were collected in heparinized tubes and centrifuged to separate the plasma at 3000 rpm for 10 min at 4 C. All the plasma samples were stored at À80 C until analysis. The thawed plasma samples (500 mL) were precipitated protein with methanol (1.5 mL). Aer vortexing for 2 min and centrifuging at 13 000 rpm for 10 min at 4 C, the supernatants were transferred to another tube and evaporated to dryness by N 2 . The residues were dissolved in methanol (150 mL) and then centrifuged again at the same manner before the UPLC-Q/TOF-MS analysis. The metabolism data were analyzed by principal components analysis (PCA) using SIMCA-P soware (version 13.0, UmetricsAB, Sweden). 2.4.2. Preparation of calibration standard and quality control (QC) samples. The mixed stock solution was obtained by mixing the accurately weighed GP and GPA methanol stock solution, and given a nal concentration of 499.20 mg mL À1 for GP, 494.00 mg mL À1 for GPA. Then the mixed solution was diluted with methanol to obtain working solutions with desired concentrations. The concentration of ginsenoside Rh1 (internal standard, IS) solution was 2 mg mL À1 . All the solutions were stored at 4 C and brought to room temperature before use.
Calibration standards and quality control (QC) samples were prepared as the following: working solution (25 mL) was evaporated to dryness by N 2 , and then blank plasma (100 mL) was added. The samples were prepared prior to the validation and pharmacokinetic study. The standards and QC samples were extracted on each analysis day with the same procedures for plasma samples as described below.
2.4.3. Preparation of the plasma samples. The IS solutions (25 mL) were added into the plasma samples (100 mL), and precipitated protein with methanol (275 mL). Aer vortexing for 2 min and centrifuging at 13 000 rpm for 10 min at 4 C, the supernatants were transferred to another tube and evaporated to dryness by N 2 . The residues were redissolved in methanol (100 mL) and centrifuged again at the same manner. Subsequently, the supernatants were transferred into vials for injection.
Method validation.
The specicity of the method was evaluated by comparing the chromatograms of blank plasma samples, plasma samples spiked with the analytes and IS, and plasma samples aer an oral dose. The calibration curves were plotted by the peak-area ratios (y) of analytes against IS vs. the nominal concentration (x). The precision and accuracy were determined from intra-and inter-batch analysis at three different QC levels, and expressed as relative standard deviation (RSD) and relative error (RE), respectively. The extraction recoveries were determined by comparing the peak areas obtained from three QC samples with those obtained from postextracted blank plasma with the pure reference standards at the same concentration. The latter peak areas compared to those obtained from the pure reference standard solutions at the same concentration for evaluation of the matrix effects. The stability was assessed using QC samples under different storage conditions: short-term stability at room temperature for 24 h, long-term stability at À20 C for 14 days, and post-preparation stability at 4 C for 24 h. Three freeze-thaw cycles (À20 C to room temperature) were used for evaluation of the freeze-thaw stability on consecutive days. 2.4.5. Pharmacokinetic study. The male Kunming mice were randomly divided into two groups (n ¼ 6 at each point). One group was administered total saponins orally at a dose of 105 mg kg À1 and the other was at 350 mg kg
À1
. Blood samples were collected in heparinized tubes at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8 and 12 h aer oral administration and centrifuged to separate the plasma at 3000 rpm for 10 min at 4 C. All the plasma samples were stored at À80 C until analysis. The pharmacokinetic parameters, including the peak plasma concentration (C max ), the time to C max (T max ), the AUC from 0 to innity (AUC 0-N ), the AUC form 0 to time (AUC 0-t ), the mean residence time (MRT) and the terminal elimination half-life (T 1/ 2z ) were calculated by the non-compartmental analysis of plasma concentration vs. time data using the "DAS 2.1.1" so-ware (Mathematical Pharmacology Professional Committee of China, Shanghai, China).
Results
Qualitative analysis of the components of total saponins
The optimal UPLC-Q/TOF-MS conditions were applied for the analysis of the total saponins. More ion information of platycosides was obtained from positive ion mode, so the positive ion mode was selected in the following investigations (Fig. 1) .
In positive mode, prominent peaks were mostly contained protonated platycoside molecules and their corresponding secondary saponin molecules. Taking the identify process of peak 5 as an example, it gave [M + H] + ion at m/z 1225 in MS that presumed as platycodin D. Meanwhile it generated the prominent ions at m/z 1093, 961, 683 and 521 as base peaks in the MS/MS by sequential lost apiosyl, xylosyl, rhamosyl, and arabinosyl residues linked at C-28, and loss of glucosyl residues linked at C-3 of the triterpene, respectively. The above rule and structure were consistent with literature of platycodin D, 26 so the peak 5 was identied as platycodin D. According to this process, peak 1, 2, 4, 5 and 7-12 were identied.
The above method was suitable for the identication of known platycosides, meanwhile the unknown compounds using reverse ideas for identifying. Taking peak 13 as the example, the prominent ion at m/z 535 was found in the positive MS/MS, and the m/z of [M + H] + ion in MS was 697, which proved this compound was platcogenic acid-type platycoside with the exact molecular weight at 696.3615. According to the fragmentations and structural characteristics, this compound was presumed as a monodesmosidic platycoside with a glucosyl at C-3 named 3-O-b-D-glucopyranosylplatyconic acid. The identi-cation of peak 3 was similar. These two platycosides were reported for the rst time, which would be separated and further conrmed in the subsequent studies if necessary. These methods were applicable for the fast and accurate identication of known and unknown platycosides. However, isomeric platycosides and constituents present at low levels were unidentiable.
As a result, thirteen platycosides that respectively belonged to paltcodic acid-and platcogenic acid-type were identied accurately and effectively (Table S1 †). The structures of these platycosides were described in Fig. S1 . †
Qualitative analysis of total saponins constituents in vivo
The PCA score plots (Fig. 2a) presented the distribution among experimental and control group based on the metabolic proles. Loading plots (Fig. 2b) indicated that markers made greater contribution to separation with farther away from original point, and the markers with the same retention time might be from the same compound.
According to the retention time and m/z of markers, nineteen markers were identied belong to seven absorbed platycosides (Table 1 and Fig. S1 †) , which were signicantly altered in the experimental group compared to the control group.
An extracted ion chromatogram (EIC) strategy was established to capture platycosides and determine their relative contents in plasma samples according to the characteristic ion pairs. The ion pair at m/z 521 and 683 was selected as the diagnostic ions for paltcodic acid-type platycosides, and platcogenic acid-type platycosides used m/z 535 and 697 as characteristic ions. The EICs (Fig. 2c and d) were shown that the relative contents of GP and GPA were higher than the primary platycosides in rat plasma aer oral administration of total saponins for 30 min. As a result, GP and GPA were determined as target compounds in the subsequent quantitative analysis in vivo.
3.3. Separation and structure identication of GP and GPA GPA (Fig. 3) was an amorphous powder and the molecular formula was assigned to be C 36 tetrahydroxyolean-12-ene-24,28-dioic acid. Other NMR spectra data were described in Fig. S2-S7 and Table S2 . † GP (Fig. 3) was identied by comparing with the spectra data reported in the literature ( 1 H and 13 C NMR are described in Table S2 and Fig. S8 and S9 †).
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Method validation for quantitative analysis
The optimized MRM modes were applied for the analysis (Table  S3 †) . No obvious endogenous interference was observed when analytes and IS were detected, and the different retention times and molecule polarity were used to distinguish platycosides that produced the same fragment ions in the plasma samples (Fig. 4) . All calibration curves exhibited good linearity (r 2 $ 0.9995).
Extraction recoveries and matrix effects of analytes and IS were in the range of 91.96-99.94% (RSD # 5.40%) and 93.45-111.65% (RSD # 8.22%), respectively. RSD of intra-and interbatch precisions were in the range of 1.19-12.28% and 1.09-6.92%, and RE from À1.18 to 9.52%, respectively ( Table 2 ). The detected concentrations for all analytes were in the range of À11.37 to 6.61% of original values, indicating that they were stable in plasma samples aer three freeze-thaw cycles, at room temperature and autosampler for 24 h, at À20 C for 14 days (partial data were described in Tables S4-S6 †) .
Pharmacokinetic study
The validated method described above was successfully applied to the pharmacokinetic study in which plasma concentrations of two analytes were determined for 12 h aer the oral administration of total saponins (105 mg kg À1 and 350 mg kg
À1
, n ¼ 6). The mean plasma concentration time proles of all analytes (Fig. 5) revealed some similarities in concentration-time curve for them, and the main pharmacokinetic parameters were exhibited in Table 3 . All analytes were quickly absorbed within 1 h, and a low peak appeared in the curve due to the enterohepatic circulation at approximately 1.5 h aer oral administration. And the ve important pharmacokinetic parameters, including
), MRT 0-t (h) and MRT 0-N (h), for GP, were lower than those of GPA at both doses of total saponins. It's worth noting that the C max (mg L
) of GPA with the dosage of 350 mg kg À1 total saponins reached 3673.10 AE 1250.44 mg L
, which was a high concentration of the drug in the plasma. Pharmacokinetic study results also showed that metabolic behaviors were similar for two secondary saponins, which made sense that GP and GPA had similar metabolic regularity. By comparing the pharmacokinetic parameters and metabolic regularity, GPA was considered to be the main absorbed platycoside in vivo.
Discussion
Jiegeng as the representative medicine of meridian-guiding theory has been shown to promote the absorption and targeted distribution of other drugs in the lungs. [29] [30] [31] Although the mechanism is not yet clear, the platycosides are considered to be the main active ingredients due to the amphiphilicity. 17, [32] [33] [34] In this study, thirteen platycosides were identied in the total saponins that isolated from the root of platycodi radix extract. Among these saponins, ten saponins belonged to primary saponins and other three were secondary saponins.
We found T max of platycodin D and platycodin D3 were both less than 1 h aer oral administration to rats in the previous pharmacokinetic studies, [21] [22] [23] 25 therefore we selected 30 min as a critical time point in metabolic qualitative research of total saponins. PCA was used qualitatively analyze the metabolites of Jiegeng in vivo, the score plots proved a signicant distinction between the experimental and control group. By analyzing the contribution value, m/z and retention time of markers in loading plots, nineteen markers were identied from seven absorbed platycosides.
Although thirteen platycosides were identied in total saponins, only seven among these were conrmed to contribute to the discrimination between experimental and control group. The result demonstrated that most of primary platycosides may be degraded or not absorbed in gastric-intestinal tract, which was in accordance with the previous reports.
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Furthermore, some differences between the metabolites in vitro and in vivo were found. The metabolites of platycosides in vivo all contained glucoses at C-3, but in vitro the glucoses could be easily hydrolyzed by enzyme that produced by intestinal bacteria; the secondary platycosides without saccharide chain at C-28 were the main absorbed compounds in vivo, but the saccharide chain at C-28 cloud not be enzymatic hydrolyzed in vitro and the main metabolites of platycosides in vitro were the compounds with the acetylated saccharide at C-28. 17, 24, 35 So the hydrolysis of saccharide chain at C-28 by gastric acid in the stomach was considered to be the main reason of the degradations of primary platycosides and the differences between the metabolites in vitro and in vivo. By comparing the relative contents obtained from peak areas in EIC, and considering the absorption and degradation of saponins, the two secondary saponins with a glucosyl linked at C-3, including GP and GPA, were used as the representative compounds in pharmacokinetic analysis.
The result of pharmacokinetic study showed that GP and GPA reached C max within 1 h aer administration in dosage of high and low, which means the rapid absorption and acting in vivo. Although the contents of GP and GPA in the total saponins were 1.03% and 0.45% respectively, the main important pharmacokinetic parameters of GP were lower than GPA. The reason could be that the acidity of GPA is stronger than GP, and the absorption of acidic compounds in the stomach is better due to gastric acid (pH ¼ 1.2). 36 On the other hand, this explains why secondary saponins containing carboxyl group at C-28 were more easily absorbed into blood than primary saponins with saccharide chain at C-28.
Based on the qualitative and quantitative results of metabolic analyses of Jiegeng in vivo, the reasons of secondary saponins as the main absorbed components are summarized as follows:
(a) The poor membrane permeability of primary saponins causes difficult to cross a biological barrier by active transport; (b) the acidic secondary saponins are easily absorbed in acidic environment of the stomach; (c) the primary saponins are hydrolysis to produce secondary saponins under the action of gastric acid. Although GPA was proved to be the most important absorbed platycoside in vivo, the further studies about the effect comparison between GP and GPA will be made in the future.
Besides a few studies on pharmacokinetics of platycodin D and D3, there have been no reports about the pharmacokinetics of the absorbed platycosides aer the oral administration of Jiegeng. The results of metabolite identication and pharmacokinetics of the absorbed saponins of Jiegeng in vivo will help researchers explore the mechanism of meridian-guiding effect in the subsequent pharmacological studies.
Conclusion
This paper developed qualitative and quantitative analyses of bioactive saponins of Jiegeng in vivo. Using the method based on the fragmentation behaviors of platycosides, a total of thirteen platycosides were identied, and seven among these were found in rat plasma aer oral administration of total saponins by PCA. A simultaneous quantitative method of GP and GPA, the major absorbed platycosides in mice plasma, was established and validated by LC-QQQ. And the pharmacokinetic parameters of the two platycosides in vivo were revealed. This investigation provided helpful information to clear about bioactive platycosides of Jiegeng in vivo, and provided pharmacokinetic data support for subsequent pharmacological researches.
